Drug Profile
Levonorgestrel intrauterine ultra low-dose - Bayer HealthCare Pharmaceuticals
Alternative Names: BAY 86-5028; Blusiri; Fleree; G04209C; Jaydess; LCS (ULD LNG); LCS - Bayer; LCS G04209B; LCS12; LCS16; Levonorgestrel contraceptive intrauterine systems - Bayer; Levonorgestrel ultra low-dose IUD; Levonorgestrel ultra low-dose IUS; LNG-IUS; LNS ultra low-dose IUD; LNS ultra low-dose IUS; Skyla; Ultra low-dose levonorgestrel intrauterine - Bayer; Ultra low-dose LNG intrauterine - BayerLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class Hormonal contraceptives; Hormonal replacements; Norpregnanes; Progesterone congeners; Small molecules
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pregnancy
Most Recent Events
- 25 Jan 2019 Levonorgestrel intrauterine ultra low-dose is not yet available for Pregnancy (Prevention) in Iceland, Germany, Bulgaria, Italy, Luxembourg, Malta, Romania, Slovakia and Slovenia (Intrauterine)
- 25 Jan 2019 Launched for Pregnancy (Prevention) in Estonia, prior January 2019 (Intrauterine)
- 25 Jan 2019 Launched for Pregnancy (Prevention) in Latvia prior January 2019 (Intrauterine)